Krystal Biotech, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Krystal Biotech, Inc. (KRYS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $15.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $15.29M, a 1.40% increase year-over-year.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $14.46M, a 0.06% increase year-over-year.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $14.21M, a 0.38% decline year-over-year.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $15.08M, a 9.40% increase year-over-year.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $58.32M, a 11.31% increase from fiscal 2024.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $52.39M, a 27.23% increase from fiscal 2023.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $41.18M, a 21.90% increase from fiscal 2022.
- Krystal Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $33.78M, a 116.50% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $15.29M 10-Q · filed 2026-08-03 | $29.74M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $14.46M 10-Q · filed 2026-08-03 | ||||
| 2025-12-31 | $58.32M 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $14.21M 10-Q · filed 2025-11-03 | $29.29M derived: sum of 2 quarters · filed 2026-08-03 | $43.73M derived: sum of 3 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $15.08M 10-Q · filed 2026-08-03 | $29.52M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2025-03-31 | $14.45M 10-Q · filed 2026-08-03 | ||||
| 2024-12-31 | $52.39M 10-K · filed 2026-02-17 | ||||
| 2024-09-30 | $14.26M 10-Q · filed 2025-11-03 | $28.04M derived: sum of 2 quarters · filed 2025-11-03 | $38.07M derived: sum of 3 quarters · filed 2025-11-03 | ||
| 2024-06-30 | $13.78M 10-Q · filed 2025-11-03 | $23.80M derived: sum of 2 quarters · filed 2025-11-03 | |||
| 2024-03-31 | $10.02M 10-Q · filed 2025-11-03 | ||||
| 2023-12-31 | $41.18M 10-K · filed 2026-02-17 | ||||
| 2023-09-30 | $8.72M 10-Q · filed 2024-11-04 | $20.16M derived: sum of 2 quarters · filed 2024-11-04 | $30.76M derived: sum of 3 quarters · filed 2024-11-04 | ||
| 2023-06-30 | $11.44M 10-Q · filed 2024-11-04 | $22.04M derived: sum of 2 quarters · filed 2024-11-04 | |||
| 2023-03-31 | $10.60M 10-Q · filed 2024-11-04 | ||||
| 2022-12-31 | $33.78M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $9.20M 10-Q · filed 2023-11-06 | $17.53M derived: sum of 2 quarters · filed 2023-11-06 | $24.10M derived: sum of 3 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $8.34M 10-Q · filed 2023-11-06 | $14.91M derived: sum of 2 quarters · filed 2023-11-06 | |||
| 2022-03-31 | $6.57M 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $15.60M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $3.75M 10-Q · filed 2022-11-07 | $8.01M derived: sum of 2 quarters · filed 2022-11-07 | $10.36M derived: sum of 3 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $4.26M 10-Q · filed 2022-11-07 | $6.61M derived: sum of 2 quarters · filed 2022-11-07 | |||
| 2021-03-31 | $2.35M 10-Q · filed 2022-11-07 | ||||
| 2020-12-31 | $3.31M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $1.36M 10-Q · filed 2021-11-08 | $2.16M derived: sum of 2 quarters · filed 2021-11-08 | $2.70M derived: sum of 3 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $807.00K 10-Q · filed 2021-11-08 | $1.35M derived: sum of 2 quarters · filed 2021-11-08 | |||
| 2020-03-31 | $539.00K 10-Q · filed 2021-11-08 | ||||
| 2019-12-31 | $1.24M 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $278.00K 10-Q · filed 2020-11-09 | $603.00K derived: sum of 2 quarters · filed 2020-11-09 | $916.00K derived: sum of 3 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $325.00K 10-Q · filed 2020-11-09 | $638.00K derived: sum of 2 quarters · filed 2020-11-09 | |||
| 2019-03-31 | $313.00K 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $792.00K 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | $279.00K 10-Q · filed 2019-11-04 | $425.00K derived: sum of 2 quarters · filed 2019-11-04 | $490.00K derived: sum of 3 quarters · filed 2019-11-04 | ||
| 2018-06-30 | $146.00K 10-Q · filed 2019-11-04 | $147.00K 10-Q · filed 2019-08-05 | $211.00K derived: sum of 2 quarters · filed 2019-11-04 | ||
| 2018-03-31 | $65.00K 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |